Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model.
We previously reported that fixed tumor sections induced autologous cytotoxic T lymphocytes (CTL) from human peripheral blood lymphocytes in vitro. Here, we examined whether fixed tumor cells could stimulate in vivo immunity using a murine hepatoma model. Vaccination of syngeneic mice with fixed Hepa 1-6 cells in combination with OK-432 and tuberculin as an adjuvant resulted in a significant increase in survival of mice against live Hepa 1-6 cell challenge. In addition, the splenocytes from vaccinated mice secreted CD4(+) T cell-mediated interferon-gamma (IFN-gamma) and exhibited a specific CTL response. These findings suggest that fixed tumor cells combined with an appropriate adjuvant induce effective antitumor immunity in vivo.
Huang
Lan
L
RIKEN Cell Bank, RIKEN, 3-1-1 Koyadai, Ibaraki 305-0074, Tsukuba Science City, Japan.
Ohno
Tadao
T
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D005557:Formaldehyde; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000276:immunology*; D051379:Mice; D023421:Models, Animal; D010844:Picibanil / Q000494:pharmacology; D011108:Polymers; D016707:Tissue Fixation
D000276:Adjuvants, Immunologic; D011108:Polymers; D005557:Formaldehyde; D010844:Picibanil; D007371:Interferon-gamma; C003043:paraform